Skip to main content

5 Result(s)

within Thomas Heinicke Remove this filter Internal Medicine Remove this filter

and

  1. Article

    Open Access

    Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

    Thomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, Heiko Trautmann… in Leukemia (2024)

    Download PDF (1088 KB) View Article

  2. No Access

    Article

    Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters

    Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could im...

    Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil… in Leukemia (2023)

  3. No Access

    Article

    Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT

    Nonmyeloablative (NMA) conditioning regimens facilitate allogeneic stem cell transplantation (alloSCT) in elderly patients and/or in those with comorbidities. The acute leukemia working party (ALWP) of the Eur...

    Thomas Heinicke, Myriam Labopin, Emmanuelle Polge… in Bone Marrow Transplantation (2020)

  4. No Access

    Article

    The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin’s Lymphoma

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option for many malignant high-risk hematological diseases. The Graft-vs.-Tumor (GvT) effect is the major hallmark ...

    Tobias A. W. Holderried, Alessia Fraccaroli… in Bone Marrow Transplantation (2019)

  5. No Access

    Article

    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

    In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation che...

    Peter Paschka, Richard F Schlenk, Daniela Weber, Axel Benner, Lars Bullinger… in Leukemia (2018)